Regeneron Pharmaceuticals (REGN)
920.69
-2.65 (-0.29%)
NASDAQ · Last Trade: Nov 20th, 5:42 PM EST
Detailed Quote
| Previous Close | 923.34 |
|---|---|
| Open | 935.80 |
| Bid | 910.00 |
| Ask | 931.00 |
| Day's Range | 916.66 - 948.42 |
| 52 Week Range | 591.52 - 991.73 |
| Volume | 880,145 |
| Market Cap | 84.50B |
| PE Ratio (TTM) | 20.32 |
| EPS (TTM) | 45.3 |
| Dividend & Yield | 3.760 (0.41%) |
| 1 Month Average Volume | 990,050 |
Chart
About Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines for serious medical conditions. The company is renowned for its cutting-edge research in areas such as genetics, biochemistry, and biology, which has led to the development of a range of therapies for diseases including cancer, eye disorders, and inflammatory conditions. Regeneron's commitment to scientific advancement and collaboration propels its pipeline of novel treatments, aimed at improving patient outcomes and addressing unmet medical needs on a global scale. Read More
News & Press Releases
Vertex and Regeneron started 2026 slowly, but blockbuster results and deep pipelines have both stocks climbing again.
Via The Motley Fool · November 19, 2026
Primary analysis from a potentially pivotal trial of Ordspono® (odronextamab) in patients with R/R marginal zone lymphoma (MZL) to be shared in an oral presentation, part of a clinical development program evaluating Ordspono across a broad spectrum of lymphoma settings
By Regeneron Pharmaceuticals, Inc. · Via GlobeNewswire · November 19, 2026
Approval based on Phase 3 NIMBLE results demonstrating rapid, deep and sustained disease control that is maintained throughout three-month dosing intervals
By Regeneron Pharmaceuticals, Inc. · Via GlobeNewswire · November 18, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) Combines High Growth Momentum With a Breakout Setupchartmill.com
Via Chartmill · November 18, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) expects its three largest growth drivers to continue supporting revenue growth, while planning higher research and development spending and preparing for a specialty drug launch, executives said at the Jefferies Healthcare Conference.
Chief Financial Officer
Via MarketBeat · November 17, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) Looks Undervalued Under the Decent Value Frameworkchartmill.com
Via Chartmill · November 3, 2026
S&P 500 Unusual Volume Movers for Nov. 2, 2026chartmill.com
Via Chartmill · November 2, 2026
Approval introduces an extended dosing regimen of Libtayo 700 mg given every six weeks, following initial 12 weeks of treatment with Libtayo 350 mg every three weeks
By Regeneron Pharmaceuticals, Inc. · Via GlobeNewswire · November 17, 2026
The stock has climbed more than 40% in one year.
Via The Motley Fool · November 14, 2026
Data presented today for the first time at the American Autonomic Society (AAS) annual meeting
By Regeneron Pharmaceuticals, Inc. · Via GlobeNewswire · November 12, 2026
S&P 500 Premarket Movers: Gainers and Losers Ahead of the Openchartmill.com
Via Chartmill · November 11, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) is advancing its experimental CIDEB therapy into later-stage studies for a form of liver disease after an early trial showed a single dose substantially reduced liver fat, executives said during an investor event.
The company said its phase 2b study in patien
Via MarketBeat · November 10, 2026
These are among the best the industry has to offer.
Via The Motley Fool · November 8, 2026
Single administration of CIDEBsiRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeks
By Regeneron Pharmaceuticals, Inc. · Via GlobeNewswire · November 8, 2026
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Via StockStory · November 4, 2026
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win...
Via StockStory · November 2, 2026
TARRYTOWN, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
By Regeneron Pharmaceuticals, Inc. · Via GlobeNewswire · November 2, 2026
Stock Market Today: Intel’s Worst Day in Four Decades Drags Chips and the Nasdaq to a Rough October Finishchartmill.com
Via Chartmill · November 2, 2026
Regeneron's third quarter was marked by strong commercial execution and pipeline momentum, with the company delivering results that topped Wall Street’s reve...
Via StockStory · November 1, 2026

An early-stage liver disease therapy cut fat by 70% in just 12 weeks, signaling the genetics engine's potential to fuel growth beyond current blockbusters.
Via The Motley Fool · October 31, 2026
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 36.3% year on year to $5.12 billion. I...
Via StockStory · October 31, 2026
S&P 500 Top Movers: Gainers and Losers in Today's US Sessionchartmill.com
Via Chartmill · October 30, 2026
What happened? Shares of biotech company Regeneron (NASDAQ:REGN) jumped 11.5% in the afternoon session after the company reported a 36% increase in third-qua...
Via StockStory · October 30, 2026
S&P 500 Top Movers: Gainers and Losers in Today's Sessionchartmill.com
Via Chartmill · October 30, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) reported third-quarter 2026 revenue growth of 36% year over year to $5.1 billion, while non-GAAP diluted earnings per share rose 70% to $20.07. The company attributed the performance to increased Sanofi collaboration revenue and continued growth from DUPIXENT,
Via MarketBeat · October 30, 2026
